A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
← catalyst calendarSponsored by Elicio Therapeutics (industry) · ELTX — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
158actual
Sites
28
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-14 | actual | When the study began enrolling |
| Primary completion | 2026-04-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pancreatic Ductal Adenocarcinoma
- Colorectal Cancer
- KRAS G12D
- KRAS G12R
- KRAS G12V
- KRAS G12A
- KRAS G12C
- KRAS G12S
- KRAS G13D
- NRAS G12D
- NRAS G12R
- NRAS G12V
- NRAS G12C
- NRAS G12S
Intervention
- Drug: ELI-002 7P
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Evaluate the safety of ELI-002 7P
measured 28 days after the first dose of ELI-002 7P
Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival)
measured After the last radiographic assessment at Visit 26 (Week 150)
Permalink · ELTX's whole pipeline · Catalyst calendar · Every registered study · What changed